Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal outcomes and had a lower risk of severe infection.
Less than half of the pregnant patients who met the criteria for thyroid screening were screened by their clinician, according to a retrospective cohort study.